文献速递白血病

癌症特异性DNA甲基化改变揭示白血病中增强子的异常沉默与激活

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
PubMed 文献 · Blood · 2016-12-21

该研究利用Illumina 450k芯片分析57例核型正常的急性髓系白血病(AML)患者,发现异常DNA甲基化主要发生在增强子区域,特定增强子的甲基化水平可预测AML患者总生存期;增强子高甲基化与增强子沉默相关,部分低甲基化位点与H3K27乙酰化增加的增强子激活相关,但DNA低甲基化不足以激活增强子,部分低甲基化发生在造血祖细胞中H3K4单甲基化标记的弱/蓄势增强子处,另一些低甲基化区域位于祖细胞中无活性位点,反映AML特异性增强子的从头获得。

要点

  • 核型正常AML中异常DNA甲基化主要发生于增强子区域。
  • 特定增强子甲基化水平可预测AML患者总生存期。
  • DNA低甲基化不足以激活增强子,部分低甲基化位点与H3K27乙酰化增加相关。

核心结论

  • 癌症特异性DNA甲基化改变揭示核型正常AML中增强子的异常沉默与激活,组蛋白变体和不同组蛋白修饰与异常DNA甲基化相互作用导致增强子活性扰动,促成白血病转录组。

研究设计与样本

  • 利用Illumina 450k芯片分析57例核型正常的AML患者。

主要发现

  • 异常DNA甲基化在增强子区域显著改变,特定增强子的甲基化水平预测AML患者总生存期。
  • AML中大多数差异甲基化位点发生在人类基因组调控元件中,高甲基化与增强子沉默相关。
  • 染色质免疫沉淀测序分析显示一部分低甲基化位点与H3K27乙酰化增加所指示的增强子激活相关,DNA低甲基化不足以激活增强子。
  • 部分低甲基化位点发生在造血祖细胞中H3K4单甲基化标记的弱/蓄势增强子处,其他低甲基化区域位于祖细胞中无活性位点并反映AML特异性增强子的从头获得。
  • 增强子动态改变反映在增强子靶基因的表达中,包括参与肿瘤发生和血细胞发育的基因。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is characterized by an impaired differentiation process leading to an accumulation of immature blasts in the blood. One feature of cytogenetically normal AML is alterations to the DNA methylome. We analyzed 57 AML patients with normal karyotype by using Illumina's 450k array and showed that aberrant DNA methylation is significantly altered at enhancer regions and that the methylation levels at specific enhancers predict overall survival of AML patients. The majority of sites that become differentially methylated in AML occur in regulatory elements of the human genome. Hypermethylation associates with enhancer silencing. In addition, chromatin immunoprecipitation sequencing analyses showed that a subset of hypomethylated sites correlate with enhancer activation, indicated by increased H3K27 acetylation. DNA hypomethylation is therefore not sufficient for enhancer activation. Some sites of hypomethylation occur at weak/poised enhancers marked with H3K4 monomethylation in hematopoietic progenitor cells. Other hypomethylated regions occur at sites inactive in progenitors and reflect the de novo acquisition of AML-specific enhancers. Altered enhancer dynamics are reflected in the gene expression of enhancer target genes, including genes involved in oncogenesis and blood cell development. This study demonstrates that histone variants and different histone modifications interact with aberrant DNA methylation and cause perturbed enhancer activity in cytogenetically normal AML that contributes to a leukemic transcriptome.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Qu Y, Siggens L, Cordeddu L, et al. Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia. Blood. 2016. PMID: 28003272. doi:10.1182/blood-2016-07-726877

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。